Comparative Pharmacology
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHAZINE DM.
NEOTRIZINE vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neotrizine contains sulfadiazine, a competitive inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
NEOTRIZINE (sulfamethoxazole/trimethoprim) 800 mg/160 mg orally every 12 hours for 5-14 days, depending on indication.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; in renal impairment, half-life may extend to 12-18 hours requiring dose adjustment.
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal elimination accounts for 20-30%, with the remainder as metabolites.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic